Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 2/20 | 0.38 |
| ▸ | AR | P10275 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 16/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | SHBG | P04278 | 1/20 | 0.34 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27062879 | 0.84 | AR (0.38) | NR3C1ARCYP19A1ESR1ESR2 | |
| SCHEMBL22917993 | 0.83 | NR3C1 (0.42) | NR3C1ARCYP19A1SLC22A1ALDH1A1 | |
| SCHEMBL24461176 | 0.83 | AR (0.37) | NR3C1ARCYP19A1ESR1ESR2 | |
| SCHEMBL24444457 | 0.83 | NR3C1 (0.42) | NR3C1ARCYP19A1SLC22A1ALDH1A1 | |
| SCHEMBL24445711 | 0.81 | AR (0.38) | NR3C1ARCYP19A1ESR1ESR2 | |
| SCHEMBL2530909 | 0.81 | AR (0.38) | NR3C1ARCYP19A1ESR1ESR2 | |
| SCHEMBL14149382 | 0.80 | CYP19A1 (0.36) | NR3C1ARCYP19A1ESR1ESR2 | |
| SCHEMBL1174533 | 0.80 | NR3C1 (0.35) | NR3C1ARCYP19A1ESR1ESR2 | |
| SCHEMBL12081921 | 0.80 | NR3C1 (0.35) | NR3C1ARCYP19A1ESR1ESR2 | |
| SCHEMBL20048228 | 0.80 | NR3C1 (0.35) | NR3C1ARCYP19A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119082-B2 | 11β-long-chain-substituted 19-nor-17α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-10-10 | — | — | US | disclosed |
| EP-1490391-B1 | 19-NOR-17ALPHA-PREGNA-1,3,5(10)-TRIEN-17BETA-OLS WITH A 21,16ALPHA-LACTONE RING SUBSTITUTED WITH A LONG CHAIN AT THE 11BETA POSITION | SCHERING AG (DE) | 2005-12-21 | — | — | EP | disclosed |
| US-20030229059-A1 | 11Beta-long-chain-substituted 19-nor-17alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring | SCHERING AG (DE) | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229059-A1 | 11Beta-long-chain-substituted 19-nor-17alpha-pregna-1,3,5(10)-trien-17beta-ols with a 21,16alpha-lactone ring | HSD17B11, CYP17A1, CYP19A1 | NR3C1 61/4885AR 95/4885CYP19A1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.